The QualityStocks Daily Tuesday, April 1st, 2025

Today's Top 3 Investment Newsletters

QualityStocks(RSLS) $1.5900 +341.05%

Premium Stock Alerts(BIAF) $1.0900 +319.23%

wyatt research newsletter(NMAX) $233.0000 +179.01%

The QualityStocks Daily Stock List

ReShape Lifesciences (RSLS)

QualityStocks, StockMarketWatch, MarketBeat, The Online Investor, BUYINS.NET, Premium Stock Alerts, Tim Bohen, StockEarnings, Premium Stock Picks, Money Wealth Matters, MarketClub Analysis, InvestorsUnderground, InvestorPlace and 360 Wall Street reported earlier on ReShape Lifesciences (RSLS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ReShape Lifesciences Inc. (NASDAQ: RSLS) (FRA: 240) is a medical device firm that is en-gaged in the provision of products and services that treat and manage metabolic illnesses and obesi-ty.

The firm has its headquarters in San Clemente, California and was incorporated in 2002. Prior to its name change in October 2017, the firm was known as EnteroMedics Inc. It serves consumers across the globe, with a focus on Europe, Australia and the United States.

The enterprise’s product portfolio comprises of a technology that is currently in pre-clinical devel-opment dubbed the diabetes Bloc-Stim neuromodulation. It has been designed to treat type 2 diabe-tes mellitus. It also provides a minimally invasive medical device known as the ReShape vest sys-tem, which is laparoscopically implanted. The device wraps around an individual’s stomach allow-ing for weight loss in morbidly obese and obese patients, without having to permanently remove portions of the stomach or undergo a gastric bypass, which involves bypassing portions of an indi-vidual’s gastrointestinal tract. The enterprise also offers a long-term minimally invasive treatment known as the Lap-band system, which has been developed to treat severe obesity and invasive surgical stapling procedures like sleeve gastrectomy or gastric bypass. Additionally, it also provides a virtual telehealth weight program that helps manage an individual’s weight, known as the Re-Share Care virtual health coaching program. The program also supports healthy lifestyle changes for weight-loss patients who are medically managed.

ReShape Lifesciences (RSLS), closed Tuesday's trading session at $1.59, up 341.0541%, on 255,080,531 volume. The average volume for the last 3 months is 22,610 and the stock's 52-week low/high is $0.3445/$29.

Alaunos Therapeutics (TCRT)

StockEarnings, QualityStocks, MarketBeat, Zacks, Trades Of The Day, MarketClub Analysis, FreeRealTime and Daily Trade Alert reported earlier on Alaunos Therapeutics (TCRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Alaunos Therapeutics Inc. (NASDAQ: TCRT) is a clinical-stage biopharmaceutical firm that is engaged in the discovery, acquisition, development and commercialization of immune-oncology therapies for cancer.

The firm has its headquarters in Houston, Texas and was incorporated in 2003, on September 9th. Prior to its name change in January 2022, the firm was known as Ziopharm Oncology Inc. It op-erates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has thirteen companies in its corporate family and serves consumers around the globe.

The company is party to a research and development agreement and a patent license agreement with the National Cancer Institute. It is also party to a research and development agreement with the MD Anderson Cancer Center. The company is also party to a license agreement with PGEN Therapeutics Inc.

The enterprise’s portfolio is comprised of a gene delivery system dubbed Ad-RTS-hIL-12 plus veledimex, which regulates IL-12 production in the treatment of patients with recurrent glioblas-toma multiforme. It also develops chimeric antigen receptor + T cell therapies which target CD19 for hematologic malignancies and T cell receptor + T therapies targeting solid tumors. The enter-prise also develops controlled IL-12 to stimulate IL-12 expression in a controlled manner, to held focus the immune system of a patient to fight cancer cells; and the Sleeping Beauty platform, which engineers T-cells.

Alaunos Therapeutics (TCRT), closed Tuesday's trading session at $2.16, up 46.9388%, on 5,410,726 volume. The average volume for the last 3 months is 9,787,516 and the stock's 52-week low/high is $1.3137/$18.5.

Sonim Technologies (SONM)

StockEarnings, QualityStocks, MarketBeat, StocksEarning, StockMarketWatch, The Stock Dork, StockRockandRoll, PennyStockLocks, Penny Stock 101, The Online Investor, PennyStocksUnited and InvestorPlace reported earlier on Sonim Technologies (SONM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonim Technologies Inc. (NASDAQ: SONM) (FRA: 2W9) is engaged in the provision of rugged-ized mobile accessories and phones for task workers.

The firm is based in Austin, Texas and was incorporated in 1999 on August 5th by Joakin Wiklund, Sudu Srinivasan, Jai Kumar, Anush Gopalan, Isaac Eteminan and Ram Chandran. Prior to its name change in December 2001, the firm was known as NaviSpin.com Inc.

The company provides solutions in 3 categories namely, cloud-based software and application ser-vices; industrial-grade accessories; and, ultra-rugged mobile devices. It sells accessories, barcode scanners and ruggedized phones through distribution channels in Europe, South America and North America and sells its accessories and mobile phones primarily to wireless carriers in Canada and the U.S. It serves defense, agriculture, transportation, utilities, oil and gas, security and con-struction industries across the globe.

Its products include a portable communications system dubbed the Rapid Deployment Kit; hands-free in-vehicle voice communication solution, multi-bay charging accessories and remote speaker microphones, which are all industrial grade accessories and the Sonim XP3, XP5s and XP8, which are all based on the android platform and can attach to private and public wireless networks. The enterprise also offers SmartScanner products like an android-based tablet called Sonim RS80 and an LTE device that’s android-based called Sonim RS60.

Sonim Technologies (SONM), closed Tuesday's trading session at $2.96, up 38.3178%, on 1,489,613 volume. The average volume for the last 3 months is 6,556,795 and the stock's 52-week low/high is $1.8674/$10.7.

GlucoTrack Inc. (GCTK)

QualityStocks, The Online Investor, Premium Stock Alerts, PennyStockProphet, Money Wealth Matters, MarketClub Analysis, InvestorsUnderground, InsiderTrades, INO Market Report and 360 Wall Street reported earlier on GlucoTrack Inc. (GCTK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GlucoTrack Inc. (NASDAQ: GCTK) is a medical device firm that is focused on designing, de-veloping and commercializing glucose monitoring devices for use by individuals suffering from diabetes and pre-diabetics.

The firm has its headquarters in Or Yehuda, Israel and was incorporated in September 2001, by David Malka and Avner Gal. Prior to its name change in November 2021, the firm was known as Integrity Applications Inc. The firm serves consumers around the globe, with a focus on the Asia Pacific, the United States, Israel and Europe.

The enterprise’s products include the GlucoTrack model DF-F, a glucose monitoring device which uses a patented combination of thermal, electromagnetic and ultrasound technologies to obtain glucose readings for pre-diabetic and diabetic patients in less than a minute, through the use of a small sensor that is clipped onto the individual’s earlobe using a Personal Ear Clip. The sensor contains calibration electronics and is linked to a handheld display and control unit. The monitoring device has been designed to obtain glucose measurements without drawing interstitial fluid or blood, making the device pain-free and needle-free. The enterprise also develops a wire-less module for the transmission of data of the glucose readings captured by the device to a cloud-based server.

GlucoTrack Inc. (GCTK), closed Tuesday's trading session at $0.225, up 28.9398%, on 12,828,169 volume. The average volume for the last 3 months is 659,125 and the stock's 52-week low/high is $0.1641/$99.

Moving iMage Technologies (MITQ)

StockEarnings, QualityStocks, MarketClub Analysis, Zacks, TipRanks, Premium Stock Alerts, BUYINS.NET and 360 Wall Street reported earlier on Moving iMage Technologies (MITQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Moving iMage Technologies Inc. (NYSE American: MITQ) is a digital cinema firm that is focused on designing, manufacturing, integrating, installing and distributing custom and standard designed equipment and other cinema products for cinema requirements.

The firm has its headquarters in Fountain Valley, California and was incorporated in September 2003 by Thomas Lipiec, Phil Rafnson, Glenn H. Sherman, David Richards, Jerry van de Rydt, Bevan Wright and Joe Delgado. It operates as part of the commercial and service industry machin-ery manufacturing industry in the United States. The firm serves consumers in Mexico, the U.S. and internationally.

The company’s services and products are focused on the needs related to the equipping, moderni-zation and building of movie exhibition theatres.

The enterprise offers proprietary rack mount pedestals; assembled and in-house designed products to support alternative auditorium configurations and boothless theatre designs; automation systems for digital cinema applications; and assembled and in-house designed dimmers and lighting prod-ucts. It also distributes cinema serves and projectors and provides demand controlled ventilation systems; premium sound systems and enclosures; and aisle lighting products, tablet arms, conces-sion trays and tables, and cup holders for theaters. This is in addition to offering Cinergy, which enables an exhibitor to manage, monitor and store digital cinema log files in a centralized and se-cure location; and software solutions, including a cinema presence management and remote control system known as CineQC.

Moving iMage Technologies (MITQ), closed Tuesday's trading session at $0.7478, up 19.648%, on 955,823 volume. The average volume for the last 3 months is 95,860 and the stock's 52-week low/high is $0.4201/$1.55.

Hut 8 Corp. (HUT)

Schaeffer's, StockEarnings, StocksEarning, MarketClub Analysis, MarketBeat, RedChip, InvestorPlace, QualityStocks, The Street, Kiplinger Today, FreeRealTime, The Online Investor, TradersPro, Zacks, Trades Of The Day, AllPennyStocks, Early Bird, Eagle Financial Publications, Daily Trade Alert and Chaikin PowerFeed reported earlier on Hut 8 Corp. (HUT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hut 8 Corp. (NASDAQ: HUT) is a blockchain infrastructure and cryptocurrency mining firm that provides blockchain infrastructure and technology solutions.

The firm has its headquarters in Toronto, Canada and was incorporated in 2011, on June 9th by Andrew Kiguel. It operates as part of the software and tech services industry, in the technology sector, under the technology services sub-industry and serves consumers in North America.

The company was established through an exclusive partnership with one of the leading blockchain technology firms in the world, Bitfury. It is led by a team of industry experts who offer investors exposure to blockchain technology and blockchain processing infrastructure, together with crypto-currency revenue from transaction fees and rewards.

The enterprise is in the business of using specialized equipment to work out complex computation-al problems that validate transactions on the bitcoin blockchain. Currently, the enterprise owns bitcoin mining data centers representing 165 PH/s and 24.2 MW, which are either under construc-tion or in operation, with a pipeline of development and acquisition opportunities across North America. It also operates and owns over 50 BlockBoxes in Alberta’s Medicine Hat and more than 30 BlockBoxes in Drumheller, which is also located in Alberta. It receives bitcoin as payment for the commercial activity of bitcoin mining.

Hut 8 Corp. (HUT), closed Tuesday's trading session at $13.32, up 14.6299%, on 10,058,990 volume. The average volume for the last 3 months is 12,351,720 and the stock's 52-week low/high is $6.95/$31.95.

Currenc (CURR)

CFN Media Group, Promotion Stock Secrets, TopPennyStockMovers, StockEarnings, QualityStocks, InvestorPlace, Premium Stock Alerts, PoliticsAndMyPortfolio, MarketClub Analysis, MarketBeat, FrontPageStocks and 360 Wall Street reported earlier on Currenc (CURR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Currenc Group Inc. (NASDAQ: CURR) is an investment holding firm engaged in the provision of real-time global payment services for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.

The firm has its headquarters in Singapore. It is also known as TNG Fintech Group. The firm serves consumers around the globe, with a focus on those in Southeast Asia.

Currenc Group is dedicated to impact investment and invests into companies that offer financial and digital inclusion to the unbanked population in the world. It is committed to creating posi-tive, scale-up social impact, and boost living standard across Asia. The company’s subsidiary is investment holding firm, Seamless Group Inc.

The enterprise operates through the remittance services and sales of airtime. The remittance seg-ment includes subsidiaries Tranglo Sdn BHD, TNG (Asia) Limited (TNGA) and related subsidi-aries (Tranglo), GEA Limited and GEA Pte Limited (GEA). Tranglo operates a remittance hub covering Southeast Asia and globally, forming the downstream segment while TNGA and GEA focus on retail remittance in Hong Kong, forming the upstream segment. On the other hand, the airtime segment operates through international airtime transfer through Tranglo and retail airtime trading in Indonesia through its subsidiary, PT Walletku Indompet Indonesia (Walletku). The en-terprise’s global network spans over 100 countries, 1500 banks/wallets, 250 mobile operators, and 60 cash pickup services with thousands of touchpoints.

The firm recently launched Seamless AI Call Center Solutions, a suite of AI-powered tools de-signed to reduce costs, increase efficiency and boost customer satisfaction for banks, telecom-munications companies, government agencies and other financial institutions. It remains commit-ted to better meeting consumer needs and generating additional value for its shareholders.

Currenc (CURR), closed Tuesday's trading session at $1.57, up 3.9735%, on 185,420 volume. The average volume for the last 3 months is 212,143,639 and the stock's 52-week low/high is $3.38/$7.76.

Marathon Digital Holdings Inc. (MARA)

MarketClub Analysis, Schaeffer's, QualityStocks, InvestorPlace, INO Market Report, StockMarketWatch, MarketBeat, StockEarnings, StocksEarning, TradersPro, Early Bird, Zacks, Premium Stock Alerts, Investors Underground, InvestorsUnderground, Lebed.biz, BUYINS.NET, The Online Investor, FreeRealTime, Trades Of The Day, CryptoCurrencyWire, 360 Wall Street, The Street, TraderPower, Daily Trade Alert, Marketbeat.com, BillionDollarClub, DailyMarketAlerts, PoliticsAndMyPortfolio, Wall Street Mover, TopPennyStockMovers, Investment House, AllPennyStocks, Wealth Insider Alert, Eagle Financial Publications, FeedBlitz, MarketClub Options, The Wealth Report, StreetAuthority Daily, Kiplinger Today, Earnings361, ProsperityPub, Barchart, RedChip, Wealth Daily, Rick Saddler, TradingPub, Trading Pub, DividendStocks, DreamTeamNetwork, Inside Trading, Stock Beast, Jeff Bishop, StockOodles, Top Pros' Top Picks, StockReport, Lance Ippolito, Promotion Stock Secrets, Investment News Daily, StreetInsider, Street Insider and Stock Analyzer reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

U.S. President Donald Trump is expanding his presence in the world of cryptocurrency. His latest move includes the introduction of a new stablecoin called USD1. This digital currency, launched by World Liberty Financial, is designed to be equal in value to the U.S. dollar. The goal is to provide a reliable digital asset that businesses and investors can use for secure transactions.

Stablecoins have become one of the fastest-growing areas in the crypto industry. Unlike Bitcoin and other cryptocurrencies that experience extreme price changes, stablecoins maintain a steady value because they are backed by real-world assets like government-issued money or gold. This makes them more suitable for everyday financial activities.

The launch of USD1 comes at a time when lawmakers in the U.S. are working on new laws to support stablecoin companies. The White House has also shown interest in these regulations, making it easier for businesses to operate in this sector.

Trump’s deep involvement in World Liberty Financial has raised some concerns. According to the company’s website, a business owned by Trump has the right to receive 75% of the company’s earnings after expenses. This financial link has led some critics to question whether it is ethical for a president to be so closely tied to a growing industry while remaining a major political figure.

In addition to the stablecoin, Trump’s company, Trump Media & Technology Group (TMTG), is working with Crypto.com to launch exchange-traded funds (ETFs). These funds will allow investors to buy a collection of cryptocurrencies and stocks with a focus on U.S.-made industries like energy. This announcement has already had a positive effect on the stock market, with TMTG’s stock price rising after the news.

Trump’s involvement in cryptocurrency has not been limited to these new projects. He has previously promoted a meme coin, a type of digital currency that often starts as a joke but can attract huge interest. He has also endorsed expensive crypto-themed merchandise, including a “Crypto President” watch worth $100,000.

While Trump was once skeptical about cryptocurrency, his views have changed over time. He now supports making the U.S. a global leader in digital assets. His growing connection to the crypto world is also linked to the strong financial support he received from the industry during his last election campaign.

Despite his efforts, some believe his deep involvement in cryptocurrency while holding political influence raises ethical concerns. However, his supporters see him as a leader who is embracing innovation and helping the industry grow. As Trump continues to expand his crypto ventures, the debate over his role in the industry is likely to continue.

Industry actors like Marathon Digital Holdings Inc. (NASDAQ: MARA) will be watching to see how the president navigates the potential conflicts of interest presented by his direct or indirect holdings in crypto businesses.

Marathon Digital Holdings Inc. (MARA), closed Tuesday's trading session at $11.84, up 2.9565%, on 35,567,767 volume. The average volume for the last 3 months is 10,491,448 and the stock's 52-week low/high is $11.05/$30.28.

Capstone Holding Corp. (CAPS)

MarketBeat, QualityStocks, Wall Street Resources, SmallCapVoice and BestOtc reported earlier on Capstone Holding Corp. (CAPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Capstone Holding Corp. (NASDAQ: CAPS) , a national building products distribution company that has successfully grown its business organically and through well-timed acquisitions, reported over 8% year-over-year revenue growth for its primary operating subsidiary, Instone, in the fourth quarter of 2024, as the company sets its sights on reaching a $100 million revenue run rate and at least $10 million in adjusted EBITDA by the end of 2025. CEO Matt Lipman emphasized the company’s commitment to doubling the business through strategic acquisitions, supported by favorable deal structures and multiple tuck-in and sister company opportunities under review. Operational highlights include the launch of Toro Stone across six states, strengthened gross margins through cost reductions, and continued national expansion in the building products sector.

To view the full press release, visit https://ibn.fm/2ycdx

About Capstone Holding Corp.

Capstone Holding Corp. is a building products distribution company that has successfully grown its business organically and through well-timed acquisitions. The company intends to use the distribution backbone of its operating subsidiary, which currently services 31 U.S. states, to provide a value-added platform to make acquisitions. A key differentiator of the company’s strategy is that it maintains over half of its revenue from brands it owns or controls. Current products include stone veneer, landscape stone, and modular masonry fireplaces. Capstone’s corporate headquarters is located in Alsip, Illinois. For more information, visit the company’s website at www.CapstoneHoldingCorp.com

Capstone Holding Corp. (CAPS), closed Tuesday's trading session at $2.34, off by 2.9046%, on 262,798 volume. The average volume for the last 3 months is 175,562 and the stock's 52-week low/high is $1.72/$16.18.

Canaan Inc. (CAN)

QualityStocks, MarketClub Analysis, Schaeffer's, StockEarnings, InvestorPlace, TradersPro, MarketBeat, CryptoCurrencyWire, AllPennyStocks, StreetInsider, Stockhouse, Dividend Report, Energy and Capital, INO Market Report, Investment Insights Report, Investors Alley, Acorn Wealth, Wealth Daily, The Online Investor, InvestorsUnderground, SmarTrend Newsletters, Stock Fortune Teller, StockMarketWatch, StocksEarning, Early Bird, The Street, BUYINS.NET, TopStockAnalysts and Trades Of The Day reported earlier on Canaan Inc. (CAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Justice Department (DOJ) announced on March 27 that it was seeking to recover roughly $23 million in crypto assets after crypto financial service firm Gotbit and its CEO and founder, Aleksei Andriunin, pleaded guilty to financial misconduct.

The legal action follows a criminal case in which a federal court in Boston accepted Gotbit’s acknowledgment of manipulating cryptocurrency trading activity. The company, operating as a market maker in the crypto asset industry, was accused of creating fake trading volumes to deceive investors about market demand and liquidity.

As part of its agreement with the DOJ, the firm agreed to relinquish the cryptocurrency linked to these operations. The DOJ stated that it had confiscated USD Coin (USDC) and Tether (USDT), which maintain their value by being pegged to the USD, from unhosted digital wallets controlled by the company.

According to prosecutors, the seized assets stem from conspiracy and wire fraud charges, as well as involvement in illicit financial activities. The case is currently under civil forfeiture proceedings and has yet to reach a final judgment.

The 26-year-old Andriunin, who is a citizen of both Portugal and Russia, was detained abroad in October last year and extradited to the United States in February.

According to authorities, Gotbit participated in a fraudulent conspiracy to manipulate crypto prices between 2018 and 2024 by using several accounts and sophisticated software. Cryptocurrencies such as Saitama and Robo Inu, which had dealings with Gotbit, are currently subject to separate investigations.

As part of the plea arrangement, the company agreed to cease all business activities and forfeit $23 million. The DOJ further stated that under the terms of the plea deal, Andriunin faces a potential sentence of up to twenty-four months in prison. Once released, he will be prohibited from engaging in any cryptocurrency-related ventures for at least three years while under supervision.

Gotbit’s lawsuit is part of a larger effort by U.S. authorities to regulate and secure cryptocurrency markets. The FBI launched NexFundAI, a digital token, last year as part of a clandestine campaign to combat fraudulent trading activities.

Gotbit was intimately implicated in the operation, collaborating with Saitama, a crypto firm based in Massachusetts, in what authorities say was a $7.5 billion market manipulation scheme. Prosecutors alleged that Saitama worked with Gotbit to inflate the token’s value while executives covertly liquidated their holdings, profiting significantly from the scam.

Other players in the crypto space, such as Canaan Inc. (NASDAQ: CAN) are likely to applaud the efforts being made by the authorities to hold to account bad players that could smear the reputation of the crypto and blockchain industry.

Canaan Inc. (CAN), closed Tuesday's trading session at $0.8672, off by 1.2076%, on 19,822,556 volume. The average volume for the last 3 months is 322,930 and the stock's 52-week low/high is $0.72/$3.27.

XTI Aerospace (XTIA)

Premium Stock Alerts, The Online Investor, RedChip, Premium Stock Picks and MarketClub Analysis reported earlier on XTI Aerospace (XTIA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

XTI Aerospace (NASDAQ: XTIA) , a developer of vertical takeoff and landing (“VTOL”) aircraft, has closed a public offering of 2,941,200 shares of common stock (or pre-funded warrants) and an equal number of accompanying warrants at a combined offering price of $1.36 per unit. The five-year warrants are immediately exercisable at the same price. Gross proceeds totaled approximately $4 million before expenses, which the company will use for general working capital and to repay outstanding secured promissory notes.

To view the full article, visit https://ibn.fm/9CuC9

About XTI Aerospace, Inc.

XTI Aerospace ( XTIAerospace.com ) (Nasdaq: XTIA) is the parent company of XTI Aircraft Company, an aviation business based near Denver, Colorado , currently developing the TriFan 600, a fixed-wing business aircraft designed to have the vertical takeoff and landing (VTOL) capability of a helicopter, speeds of 345 mph and a range of 700 miles, creating an entirely new category – the vertical lift crossover airplane (VLCA). Additionally, the Inpixon ( inpixon.com ) business unit of XTI Aerospace is a leader in real-time location systems (RTLS) technology with customers around the world who use the Company’s location intelligence solutions in factories and other industrial facilities to help optimize operations, increase productivity, and enhance safety.

For more information, visit the company’s website at https://xtiaerospace.com/

XTI Aerospace (XTIA), closed Tuesday's trading session at $1.04, off by 4.5872%, on 532,427 volume. The average volume for the last 3 months is 1,179,957 and the stock's 52-week low/high is $0.0013/$0.0015.

Cronos Group Inc. (CRON)

InvestorPlace, Schaeffer's, QualityStocks, Kiplinger Today, MarketClub Analysis, StocksEarning, The Street, MarketBeat, Daily Trade Alert, Trades Of The Day, The Online Investor, Wealth Insider Alert, StockEarnings, Market Intelligence Center Alert, StockMarketWatch, StreetInsider, CannabisNewsWire, BUYINS.NET, The Wealth Report, Zacks, Investopedia, Top Pros' Top Picks, Stock Up Featured, Daily Profit, Cabot Wealth, InvestmentHouse, Jim Cramer, Early Bird, InsiderTrades, The Rich Investor, Money Morning, InvestorsUnderground, 24/7 Trader, TheTradingReport, VectorVest, Wall Street Window, Small Cap Firm, Stock Gumshoe and InvestorsObserver Team reported earlier on Cronos Group Inc. (CRON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pennsylvania lawmakers are stepping up their scrutiny of the state’s medical cannabis program following investigative reports by Spotlight PA.

A recent measure aimed at increasing oversight of doctors involved in the program gained strong bipartisan support in the state House, moving forward in March.

Additionally, state Senator Rosemary Brown cited the newsroom’s reports while questioning officials from the Shapiro administration. Brown raised concerns about medical cannabis prescribing practices during a budget hearing in February, asking what measures were in place to prevent potential abuses.

Her concerns align with investigations revealing that some doctors approve a disproportionately high number of medical cannabis certifications. Additionally, the Pennsylvania Health Department has rarely barred physicians from joining the medical cannabis program, even when they had prior disciplinary issues.

State Representative Tim Twardzik used the Spotlight PA reports to advocate for stronger oversight powers for the state’s health department. He argued that clear authority is needed to ensure patients receive proper care.

Pennsylvania’s medical cannabis law requires patients to obtain a doctor’s certification to access marijuana from dispensaries. Doctors must complete a training course and register with the state to issue these approvals.

Twardzik’s measure would give the state’s health department greater control over participating doctors. In addition to limiting the number of certificates a physician can grant, the agency may enforce reporting requirements, impose probation, and demand supervision by another medical practitioner. The department would also have the authority to introduce additional regulations as needed to protect patient safety.

State Representative Arvind Venkat, a physician who doesn’t issue medical cannabis certifications, voiced support for the measure, emphasizing the need for better oversight. He acknowledged that addressing these concerns may be difficult for doctors, but necessary.

The proposal was unanimously approved by the House Health Committee as an amendment to a bill focused on cannabis lab testing, sponsored by state Representative Dan Frankel.

Frankel highlighted that while laboratories are required to test cannabis products, the health department currently lacks the power to oversee their operations and verify results. The amended bill was approved by the House and is now under review by the Senate Law and Justice Committee.

State Senate leaders have expressed interest in amending the state medical cannabis program. Joe Pittman, the Senate Majority Leader, acknowledged the need for a detailed review of the bill but noted that action on the measure is possible within the current legislative session.

Minority Leader Jay Costa voiced his caucus’s support, stating that stronger oversight would protect patients from unethical practices and contaminated products. Costa also reaffirmed his ultimate goal of legalizing recreational marijuana.

Governor Josh Shapiro has included recreational marijuana legalization in his budget proposal, despite previous efforts to pass such legislation having stalled.

It is important to ensure that legal marijuana markets adhere to all the set rules and that observed loopholes are addressed by the authorities. Firms like Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) operating in other regulated markets are therefore likely to applaud the increased oversight envisioned in the bills being considered in Pennsylvania.

Cronos Group Inc. (CRON), closed Tuesday's trading session at $1.79, off by 1.105%, on 784,533 volume. The average volume for the last 3 months is 309,999 and the stock's 52-week low/high is $1.72/$3.14.

The QualityStocks Company Corner

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF) , an innovator in hospitality automation, has acquired Skytech Automated Solutions, Inc., a leader in AI-driven service technologies for hotels. This strategic move follows Nightfood's recent acquisition of Carryout Supplies and enhances its Robotics-as-a-Service (RaaS) offerings. Skytech's Laundry Helper robot, already in use at multiple hotel properties, will now be integrated into Nightfood's broader automation platform to improve operational efficiency and guest experience. The combined capabilities are expected to boost market reach, recurring revenue, and operational scalability.

To view the full press release, visit https://ibn.fm/Mtbgi

Nightfood Holdings Inc. (OTCQB: NGTF) is a hospitality technology and asset acquisition company revolutionizing hotel operations through AI-driven service robotics and strategic property acquisitions. By integrating advanced automation solutions with high-value hospitality assets, NGTF is setting a new standard for operational efficiency, cost reduction, and labor optimization in the hospitality industry.

With a focus on Robotics-as-a-Service (RaaS) and hotel ownership, NGTF is uniquely positioned at the intersection of technology and real estate, creating scalable, revenue-generating solutions that drive the widespread adoption of automation in the hospitality sector.

Operations

Nightfood Holdings is focused on two core business areas:

  • Hotel Acquisitions & Operations – NGTF is acquiring a portfolio of independent hospitality properties, spanning various market segments from midscale to luxury. These hotels serve as real-world testbeds for automation technologies, allowing NGTF to refine its RaaS solutions before deploying them at scale.
  • Robotics-as-a-Service (RaaS) for Hospitality – NGTF provides subscription-based, AI-driven robotic automation, designed to optimize hotel operations. By deploying standardized automation solutions, NGTF helps hotels reduce costs, improve labor efficiency, and enhance guest experiences.

Through this fully integrated model, NGTF ensures that its robotics solutions are tested, optimized, and proven profitable before expanding to third-party hotel operators.

Market Opportunity

The demand for automation in hospitality is accelerating, driven by labor shortages, rising costs, and increased competition. NGTF is positioned to capitalize on this shift through its combined hotel ownership and RaaS strategy.

  • Total Addressable Market (TAM): The global service robotics market is projected to reach approximately $107.75 billion by 2030, driven by widespread adoption across industries including hospitality, according to Research and Markets.
  • Serviceable Available Market (SAM): The global smart hospitality market, which includes AI and automation technologies for hotels, is projected to reach $186.10 billion by 2032, according to SNS Insider.
  • Competitive Positioning: NGTF’s unique real estate + automation model allows it to implement cost-saving robotics solutions in real-world environments before expanding adoption across the industry.

Industry Impact: The Future of Smart Hotels

NGTF is at the forefront of next-generation hospitality automation, transforming how hotels operate. By combining AI-powered service robotics with real estate acquisitions, NGTF is pioneering the transition to smart, highly efficient hotel environments.

Hotels acquired by NGTF serve as testing grounds for robotics deployment, allowing the company to continuously refine its automation solutions. The biggest industry benefits include:

  • Cost Savings for Hotel Operators – Reducing labor costs and improving operational efficiency.
  • Scalability & Standardization – Offering a streamlined, subscription-based RaaS model for seamless automation adoption.
  • Industry Leadership in Hotel Robotics – Driving the transformation of hospitality with AI-powered automation solutions.

Future Vision & Growth Strategy

Over the next three to five years, NGTF is committed to scaling both its hotel portfolio and RaaS adoption. By refining and optimizing its automation technologies in its own properties, NGTF will continue deploying RaaS to third-party hotel operators, positioning itself as a leader in next-generation hospitality automation.

Through strategic acquisitions and AI-driven solutions, NGTF is defining the future of smart hotels—delivering cost-efficient, scalable automation that reshapes the hospitality landscape.

Team Expertise as a Strategic Advantage

In addition to technology and real estate, NGTF’s most powerful asset is its team. The company’s leadership and operating partners bring deep expertise in both hospitality and food service, having collectively developed over 50 properties, managed more than 130 hotels, and supported more than 6,000 quick-service restaurants.

This wealth of experience enables NGTF to execute its automation and acquisition strategy with operational discipline, industry insight, and scale—further strengthening its position in next-generation hospitality.

Investment Considerations
  • Dual Growth Strategy – NGTF combines hotel acquisitions with AI-powered automation, creating an integrated model that maximizes operational efficiency and revenue potential.
  • Expanding Robotics-as-a-Service (RaaS) – Subscription-based robotic automation solutions designed to reduce operational costs and address labor shortages for hotel operators.
  • Strategic Hotel Acquisitions – Acquiring a variety of hospitality assets, from midscale to luxury, to serve as testing grounds for AI-driven automation and to drive profitability.
  • Proven Market Demand – Rising labor costs and increasing adoption of service robotics are fueling demand for automation in hospitality, positioning NGTF as an early leader in the sector.
  • Scalable & Revenue-Generating Model – By owning hotels and offering RaaS to third-party operators, NGTF is building a diversified, high-growth business model.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Tuesday's trading session at $0.03, up 240.9091%, on 42,753 volume. The average volume for the last 3 months is 400,670 and the stock's 52-week low/high is $0.0053/$0.035.

Recent News

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)

The QualityStocks Daily Newsletter would like to spotlight Quantum BioPharma Ltd. (NASDAQ: QNTM) (OTC: QNTM).

Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company advancing innovative biotech assets, announced a joint clinical study with Massachusetts General Hospital to evaluate a novel PET imaging technique for tracking myelin integrity in multiple sclerosis (MS) patients. The study will assess [18F]3F4AP PET scans as a biomarker for demyelination, complementing MRI scans in both progressive and relapsing-remitting MS. The technique may enhance diagnostics in trials involving remyelinating and neuroprotective drugs, including Quantum's Lucid-MS, which has shown promise in preserving the myelin sheath in preclinical models.

To view the full press release, visit https://ibn.fm/IQlIn

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd™, a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

The company’s vision is to revolutionize healthcare solutions for underserved markets, guided by a mission to enhance lives through science and innovation. By leveraging its expertise in medicinal chemistry and product commercialization through joint ventures, Quantum BioPharma aims to make significant strides in its targeted sectors.

Quantum BioPharma is headquartered in Toronto, Canada.

Lucid-MS

Lucid-MS is Quantum BioPharma’s flagship therapeutic candidate for the treatment of multiple sclerosis (MS). This new chemical entity (NCE) is the result of over 14 years of preclinical research and has demonstrated the potential to stop and even reverse myelin degradation, a known cause of MS. Unlike current treatments, Lucid-MS offers a neuroprotective approach without immunosuppression, addressing a critical unmet need in the MS market.

With nearly one million people in the U.S. living with MS and over 2.8 million cases globally, Lucid-MS targets a vast market with significant demand for better treatment options. In December 2024, Quantum BioPharma announced promising news from its ongoing phase 1 trial of Lucid-MS – a safety review committee recommended starting the dosing of the trial’s second cohort. Lucid-MS represents a transformative opportunity in the treatment of demyelinating diseases. The company is leveraging an expedited regulatory pathway to reach patients faster and has indicated that a phase 2 clinical trial is likely on the horizon.

Celly Nutrition and unbuzzd™

Quantum BioPharma’s product portfolio is anchored by unbuzzd, a dietary supplement in both powder stick and 12 oz. RTD beverage formats, developed by Quantum and licensed to Celly Nutrition, designed to accelerate alcohol metabolism and restore mental alertness within minutes. This clinically tested first-to-market solution utilizes a proprietary blend of extracts, vitamins, and minerals to reduce blood alcohol concentration (BAC) and improve cognitive function post-alcohol consumption. Launched in August 2024, unbuzzd is part of a growing consumer market for hangover remedies, but unique with its effectiveness in rapidly reducing BAC.

The product’s innovative formulation sets it apart as the only clinically tested, effective dietary supplement beverage targeting alcohol detoxification. Its multi-channel distribution strategy includes direct-to-consumer sales through e-commerce platforms, retail partnerships, and on-premise marketing initiatives. Quantum BioPharma’s focus on consumer education and strategic partnerships positions unbuzzd for significant growth within the expanding hangover remedy market.

Market Opportunity

Quantum BioPharma operates in sectors with significant growth potential. The global market for hangover remedies was valued at $2.05 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 14.8%, reaching $6.2 billion by 2030, according to Grand View Research. This growth is fueled by increasing consumer demand for effective alcohol detoxification solutions and rising awareness of products like unbuzzd.

Similarly, the global multiple sclerosis market is projected to grow from $28.2 billion in 2022 to $41 billion by 2033, driven by advancements in treatment options and an increasing prevalence of MS cases worldwide.

Quantum BioPharma’s dual focus on consumer health products and high-value therapeutics uniquely positions it to capitalize on these opportunities. Its strategic investments and innovative R&D pipeline provide a competitive edge in addressing unmet needs in both markets.

Leadership Team

Zeeshan Saeed, CEO and Co-Founder of Quantum BioPharma, has extensive experience in international capital markets and a proven track record of successfully assisting startups in raising initial funding. Under his leadership, Quantum BioPharma has developed a robust portfolio of innovative products and strategic investments.

Gerry David, Director and Co-Chair of Celly Nutrition, brings decades of experience in consumer-packaged goods (CPG) and is best known for his tenure as CEO of Celsius Holdings. During his leadership, he increased the company’s valuation by 35-fold, surpassing $9 billion. His expertise in scaling product distribution programs has been instrumental to Quantum BioPharma’s strategic initiatives.

John Duffy, CEO of Celly Nutrition, has over two decades of leadership experience in the Coca-Cola system, where he served as Vice President of National Sales. His expertise in customer management and sales strategy is driving the success of unbuzzd’s market rollout.

Investment Considerations
  • Proprietary R&D is led by a world-class team of medicinal chemists and industry veterans, ensuring innovative product development.
  • A first-to-market product, unbuzzd addresses a fast-expanding consumer category, with 300% growth expected by 2030.
  • Lucid-MS, a potential multi-billion-dollar asset, represents a significant breakthrough in the treatment of demyelinating diseases, supported by an expedited regulatory pathway.
  • Strategic equity and royalty agreements with Celly Nutrition for consumer-focused alcohol misuse treatments provide an additional revenue stream.
  • Quantum BioPharma is strategically positioned in two high-growth sectors: hangover remedies and MS therapeutics.

Quantum BioPharma Ltd. (NASDAQ: QNTM), closed Tuesday's trading session at $7.99, up 3.6316%, on 3,160 volume. The average volume for the last 3 months is 1,215,632 and the stock's 52-week low/high is $2.7/$46.8.

Recent News

Thumzup Media Corp. (NASDAQ: TZUP)

The QualityStocks Daily Newsletter would like to spotlight Thumzup Media Corp.(NASDAQ: TZUP).

Thumzup (NASDAQ: TZUP) , a rising AdTech player in social media branding and programmatic marketing, announced it has exceeded 800 advertisers on its platform, with expectations to cross 1,000 by mid Q2 2025. The company reported a 243% compound annual growth rate, fueled by strategic expansion into South Florida, Miami, and Greater Salt Lake City. Thumzup's platform integrates with major social networks, including Instagram Reels and X, reaching over 535 million users monthly.

To view the full press release, visit https://ibn.fm/v8bFY

Thumzup Media Corp. (NASDAQ: TZUP) is at the forefront of modernizing the social media branding and marketing industry with its unique platform designed to connect advertisers directly with everyday social media users. The company’s mission is to empower individuals by turning their authentic social media activity into a monetizable asset while providing brands with cost-effective and impactful advertising solutions.

Through its flagship Thumzup platform, the company offers a seamless system where users post about participating advertisers and receive cash payments via Venmo or PayPal. Thumzup recently announced plans to integrate bitcoin as an additional payment option, expanding accessibility for gig economy workers.

By prioritizing accessibility and transparency, Thumzup is redefining traditional marketing strategies with an inclusive, user-driven approach. It is leveraging its scalable technology to disrupt the status quo, offering a win-win ecosystem for advertisers and users alike.

The company is headquartered in Los Angeles, California.

Products

Thumzup’s key offering, the Thumzup platform, features two integrated components: a sophisticated advertiser dashboard and an intuitive consumer-facing app. The advertiser dashboard provides companies with tools to design, manage, and analyze campaigns.

On the consumer side, the Thumzup app allows users to participate in campaigns by posting approved content to their social media accounts. In exchange, users receive direct cash rewards.

Recent enhancements to the platform include the launch of video capabilities, enabling integration with Instagram Reels. This update allows advertisers to tap into the growing popularity of short-form video content, broadening campaign possibilities.

The platform not only incentivizes users but also delivers authentic, relatable content for advertisers, bridging the gap between grassroots engagement and effective campaign management.

Market Opportunity

The global social media advertising market is projected to reach $219.8 billion in 2024, with an expected annual growth rate of 3.86%, resulting in a market volume of $255.8 billion by 2028, according to Statista. Thumzup targets the intersection of this growth with the rise of micro-influencers and everyday social media users, a segment that remains largely untapped in the advertising ecosystem.

In October 2024, Thumzup achieved 202% year-over-year growth in advertisers on its proprietary platform, demonstrating significant traction and scalability. With plans for further expansion in both advertiser partnerships and user engagement, the company is well-positioned to capitalize on the growing demand for authentic and trust-building marketing strategies. As Thumzup integrates innovative features like video support and continues its geographic expansion, it is poised to capture a larger share of the rapidly growing social media advertising market.

Leadership Team

Robert Steele, Founder and Chief Executive Officer of Thumzup, has over 25 years of experience as a technologist and entrepreneur. He has successfully launched multiple companies, including iBrite, a pioneer in mobile software development. Mr. Steele’s leadership and innovative vision drive Thumzup’s mission to democratize the social media marketing industry.

Robert Haag, Director of Thumzup, is the Managing Member of Westside Strategic Partners LLC and a Managing Director at IRTH Communications. With decades of experience in financial communications, investment, and corporate strategy, Mr. Haag provides critical guidance on strategic initiatives and business growth.

Dr. Joanna Massey, member of the company’s Board of Advisors, brings over 25 years of executive experience with Fortune 500 companies and startups to Thumzup. She has held senior roles in communications at Lions Gate Entertainment and CBS Corporation. Dr. Massey leverages her expertise to support Thumzup’s growth strategy.

Thumzup Media Corp. (NASDAQ: TZUP), closed Tuesday's trading session at $4.12, up 1.9802%, on 4 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.02/$7.89.

Recent News

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Nissan Motor is set to unveil a crossover version of the Nissan Leaf EV with an impressive 373-mile range. The Japanese automaker recently released teaser images of the updated electric vehicle, dubbed the 2026 Leaf, but has not yet revealed major details about the forthcoming update to its iconic Nissan Leaf EV. As a crossover, the new Nissan Leaf will differ significantly from prior versions, marking a strategic shift in Nissan's approach to remain competitive in the evolving EV market. With Chinese manufacturers like BYD flooding the market with lower-cost EVs, Nissan is facing increased pressure to maintain a strong presence in Asia's vehicle sector. Despite facing fierce competition, Nissan has played a crucial role in the global EV revolution. As one of the first major automakers to introduce a mass-market electric vehicle, Nissan demonstrated the viability of electric cars to mainstream consumers and helped normalize EV adoption. With the 2026 Leaf's crossover design and extended range, Nissan aims to reassert its presence in the rapidly evolving EV industry. The NEV market is promising to be extremely competitive as Nissan joins other firms like Massimo Group (NASDAQ: MAMO) in a bid to dominate the different segments of the industry where they have interest.

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

  • Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
  • Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
  • Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Investment Considerations
  • Massimo Group operates within a large and growing total addressable market that’s projected to surpass $18 billion by 2026.
  • The company’s cost-competitive and feature-rich products, including all-electric offerings, provide a strong value proposition.
  • Recent automation initiatives at its Texas factory are expected to improve manufacturing efficiency by an estimated 50%.
  • During the first three quarters of 2024, revenue increased by 20.8% to $91.2 million compared to the same period in 2023, reflecting strong market demand and successful product launches.
  • Strategic partnerships, such as those with Vision Marine and Rural King, enhance Massimo’s market reach and growth opportunities.
  • Consistent innovation, as seen in the launches of the T-Boss 1000 and MVR Series, is expected to drive Massimo’s push to be a leader in its industry.

Massimo Group (NASDAQ: MAMO), closed Tuesday's trading session at $2.73, up 1.1111%, on 8,631 volume. The average volume for the last 3 months is 10,808 and the stock's 52-week low/high is $2.42/$4.66.

Recent News

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings (NASDAQ: BREA) , an Ireland-based company advancing a multi-club ownership model in global football, celebrated the legacy of Advisory Board member and former Italy international Giuseppe Rossi during Fiorentina's Pepito Day on March 22 in Florence. The tribute at Stadio Artemio Franchi featured tributes from fans, football legends, and Rossi's former coaches, recognizing his career-defining moments and contributions to the sport. Brera's executive team and investors attended both the match and a gala in Rossi's honor, reflecting his ongoing influence on the company's community-first strategy.

To view the full press release, visit https://ibn.fm/YVfx0

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Additional Resources

Brera Holdings PLC (NASDAQ: BREA), closed Tuesday's trading session at $0.6802, up 4.0061%, on 17,075 volume. The average volume for the last 3 months is 303,938 and the stock's 52-week low/high is $0.4999/$1.95.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

The price of gold has risen significantly over the last couple of weeks, trading at $3077.30 per ounce by the end of last week. Thus far this month, the metal's price has risen by 8%, with analysts expecting that it could end the quarter with a 17% increase. Gold has historically been viewed as a hedge against inflation and economic uncertainty. Previous rallies in gold prices have often coincided with periods of high geopolitical risk, inflationary pressures, or recession fears. Following this announcement, the Office of Canadian PM Mark Carney released a statement declaring that they would enforce retaliatory tariffs on American goods in response to the promised import taxes. These trade tensions could further boost gold prices as tariffs generally contribute to inflationary pressures, leading investors to seek protection in precious metals. Investor interest is also likely to be directed toward firms like Aston Bay Holdings Ltd. (TSX.V: BAY) (OTQB: ATBHF) that focus on developing gold-rich mineral properties.

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.

Projects

Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Tuesday's trading session at $0.035, up 12.9032%, on 23,000 volume. The average volume for the last 3 months is 175,230 and the stock's 52-week low/high is $0.03095/$0.107.

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

Elon Musk recently announced that his AI company, xAI, has acquired X, the social media platform he bought in 2022. The sale, which includes $12 billion in debt, is worth $45 billion, marginally more than Musk's initial purchase price. Posting on X, Musk noted that combining xAI's capabilities with X's vast user base would create new opportunities. While no imminent improvements to X were announced, xAI's AI chatbot, Grok, is already integrated into the platform. Musk suggested that the merger would lead to more intelligent and engaging user experiences. The combined entity, he estimated, is now worth around $80 billion. If this divestiture is a harbinger of the expected consolidation within the AI space, entities like D-Wave Quantum Inc. (NYSE: QBTS) will be watching to see what similar activity emerges as the race for dominance in the AI space heats up.

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $7.42, off by 2.3684%, on 718,593 volume. The average volume for the last 3 months is 80,367,345 and the stock's 52-week low/high is $0.7505/$11.95.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1×1 investor meetings. A webcast of the presentation will be available via the events section of Clene's website.

To view the full press release, visit https://ibn.fm/rK99F

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $2.58, off by 16.2338%, on 327 volume. The average volume for the last 3 months is 49,719 and the stock's 52-week low/high is $2.57/$9.2.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026.

To view the full press release, visit https://ibn.fm/NoBcQ

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $1.29, off by 5.1471%, on 979 volume. The average volume for the last 3 months is 412,098 and the stock's 52-week low/high is $1.21/$950.

Recent News

Calidi Biotherapeutics Inc. (NYSE American: CLDI)

The QualityStocks Daily Newsletter would like to spotlight Calidi Biotherapeutics Inc. (NYSE American: CLDI).

Cutaneous melanoma is the most aggressive skin cancer type and it is characterized by manifesting diverse mutations. Under normal circumstances, several of these mutations could be identified as threats by the immune system, but in this type of cancer, this doesn't happen. Consequently, most patients are unresponsive to immunotherapy. This challenge has baffled oncology researchers for years. Now new research conducted by CNIO Melanoma Group located at the National Cancer Research Center in Spain has discovered the mechanism through which aggressive tumors like cutaneous melanoma evade the immune system in a way that isn't expected. The CNIO team also analyzed several data sets taken from large patient cohorts and saw that gene signatures connected to Midkines resulted in worse prognosis for the patients. Midkine activity manifested in not just cutaneous melanoma but also in other cancers like adrenal gland, breast, endometrium, mesothelium, lung and other cancers. These insights could provide immune-oncology firms like Calidi Biotherapeutics Inc. (NYSE American: CLDI) with valuable factors to consider in their quest to commercialize the next generation of immune therapies against solid tumors.

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for 6,053,000 shares. Proceeds will support working capital and advance Calidi's clinical and preclinical cancer therapy programs.

To view the full press release, visit: https://ibn.fm/mvx3d

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering proprietary technology that empowers the immune system to combat cancer. Calidi’s innovative, off-the-shelf cell-based platforms use allogeneic stem cells to deliver potent oncolytic viruses (OVs) across multiple oncology indications, including high-grade glioma (brain cancers) and solid tumors. In addition, Calidi has presented a breakthrough systemic technology, RTNova, which utilizes an exteracellular enveloped virotherapy. RTNova is pre-clinical and has been extremely well-received by market analysts and large-cap biopharma – opening the door for potential collaboration.

These cell-based platforms are engineered to protect, amplify, and enhance the efficacy of oncolytic viruses, resulting in improved patient safety and potentially advancing treatment outcomes for metastatic disease. By employing a dual approach that combines OV delivery with immune activation, Calidi’s therapies aim to not only treat but potentially prevent the spread of metastatic cancers.

The company’s development pipeline leverages this technology to address pressing needs in cancers such as glioblastoma (brain cancer), metastatic melanoma, triple-negative breast cancer, head & neck cancer, and lung cancer. Calidi’s approach has shown early signals of efficacy and safety, establishing it as a distinctive player in the growing OV market, which is projected to increase significantly in value over the next decade.

Calidi is headquartered in San Diego, California.

Products

Calidi’s product pipeline includes advanced cell-based platforms targeting a variety of oncology indications, each designed to harness the power of oncolytic virotherapy for improved cancer treatment outcomes.

  • NeuroNova (CLD-101): A platform designed for treating high-grade gliomas (HGG), NeuroNova employs neuronal stem cells combined with an engineered adenovirus (CRAD-s-Pk7) to selectively target glioma cells. After a successful Phase 1 safety study in newly diagnosed HGG, NeuroNova has now progressed into Phase 1/1b trials for recurrent cases. FDA clearance for a Phase 1b/2 trial at Northwestern University was received in September 2024, with patient enrollment expected to begin in Q1 2025. This trial will utilize multiple-dose intracerebral administration to maximize safety and efficacy in newly diagnosed HGG patients.
  • SuperNova (CLD-201): Built on Calidi’s foundational technology, SuperNova utilizes an engineered Vaccinia virus (CAL1) delivered via allogeneic adipose-derived mesenchymal stem cells to target advanced solid tumors, including head & neck, triple-negative breast cancer, and soft tissue sarcomas. Early studies with autologous stem cells demonstrated both safety and promising efficacy, and Calidi plans to begin a Phase 1 trial with multiple dose regimens for SuperNova in the coming months.
  • RTNova (CLD-400): Calidi’s systemic delivery platform for lung and metastatic cancers, RTNova employs an extracellular enveloped virotherapy (envRT-01) technology for intravenous (IV) administration, simplifying the treatment process and expanding its potential applications. Currently in preclinical stages, RTNova focuses on demonstrating efficacy and safety through systemic administration. A clinical trial targeting metastatic lung cancer is anticipated for Q2 2026, using a single-arm monotherapy with dose escalation. Calidi has partnered with SIGA Technologies (NASDAQ: SIGA) to support the development of this program.

Market Opportunity

The global oncology drugs market was valued at $201.75 billion in 2023 and is projected to grow to $518.25 billion by 2032, with a CAGR of 11.3%. The oncolytic virotherapy market in particular is growing rapidly, driven by increasing approval rates and significant unmet needs.

The market for OV treatments is expected to expand from one approved product generating $150 million in the U.S. in 2021 to 6-8 approved therapies generating $2.4 billion by 2030. As a leader in OV technology, Calidi is well-positioned to address these high-demand areas in oncology.

Alongside global trends, the American Cancer Society projects nearly two million new cancer diagnoses in the U.S. in 2024, reflecting a 28% increase since 2010. This underscores the urgent need for novel therapies that not only treat disease progression but also enhance patient quality of life, reinforcing the demand for Calidi’s innovative approaches.

Management Team

Allan Camaisa, CEO, Chairman, and co-founder, is a seasoned leader with extensive experience in scaling businesses to successful exits. Mr. Camaisa previously led High Technology Solutions, growing it from two employees to over 500 with $50 million in revenue. He also served as CEO of Parallel6 Inc. and is a U.S. Naval Academy graduate with further studies at Harvard Business School.

Antonio Santidrian, Ph.D., Chief Scientific Officer, leads all research and development initiatives at Calidi and is the coinventor of the company’s CLD-201 (Supernova) and CLD-400 (RTNova) platforms. Since joining Calidi in 2015, he has applied his 20+ years of expertise in academia and biotech, focusing on anti-cancer translational research, to drive the company’s innovative drug pipeline. Before Calidi, Dr. Santidrian led translational studies at The Scripps Research Institute, advancing treatments for breast cancer metastasis, and contributed to the development of ACADRA for chronic lymphocytic leukemia (CLL) at the University of Barcelona, Spain.

Boris Minev, M.D., President of Medical and Scientific Affairs, is a renowned physician-scientist with expertise in Immuno-Oncology, stem cell biology, and oncolytic viruses. Previously, Dr. Minev served as Director of Immunotherapy and Translational Oncology at Genelux Corporation and remains an adjunct professor at the Moores UCSD Cancer Center. His background includes research at the National Cancer Institute.

Andrew Jackson, CFO, has held executive finance roles with experience in biotech and clinical-stage companies, including Eterna Therapeutics and Ra Medical Systems. Mr. Jackson holds an MSBA in Finance from San Diego State University and a BSB in Accounting from the University of Minnesota.

Calidi Biotherapeutics Inc. (NYSE American: CLDI), closed Tuesday's trading session at $0.5571, off by 1.6072%, on 2,353 volume. The average volume for the last 3 months is 473,090 and the stock's 52-week low/high is $0.5301/$8.3.

Recent News

FAVO Capital Inc. (OTC: FAVO)

The QualityStocks Daily Newsletter would like to spotlight FAVO Capital Inc. (NASDAQ: FAVO).

FAVO Capital Inc. (OTC: FAVO) is redefining the private credit and alternative lending industry through a strategic redevelopment of its operations and offerings. With a focus on leveraging financial technology and a client-centric approach, FAVO Capital empowers small to medium-sized businesses with fast, flexible, and reliable access to capital, bridging the gap left by traditional financial institutions.

Empowering Businesses, Redefining Private Credit

As part of its strategy to uplist to Nasdaq, FAVO Capital is enhancing its technology platform, operational scalability, and market positioning to meet higher regulatory standards and attract institutional investors. Headquartered in Fort Lauderdale, Florida, FAVO employs over 120 professionals across five global offices, delivering sustainable growth and value for clients and shareholders alike.

Products and Services

  • Proprietary Lending Platform and Mobile App (In Development): FAVO Capital is in the early stages of developing an advanced digital platform designed to enhance client engagement and streamline funding processes. This platform will eventually allow businesses to apply for funding products, track progress, and manage repayment efficiencies. A complementary mobile app is also being planned to provide real-time insights and tailored recommendations, laying the groundwork for an improved borrower experience.
  • Fintech-Driven Lending Solutions: FAVO Capital is exploring proprietary and third-party technology tools, including advanced analytics and algorithms, to enhance decision-making speed and reliability in the lending process.
  • Flexible Financing Options: FAVO specializes in structuring customized capital solutions tailored to the diverse needs of small business owners, offering scalable and adaptable products that evolve with changing market conditions.

Market Opportunity

The private credit market is experiencing exponential growth as traditional banks reduce their focus on small business lending. According to industry reports, the global private credit market is projected to surpass $1.5 trillion by 2025, driven by increasing demand for alternative financing options.

FAVO Capital is uniquely positioned to capture market share within this booming sector by leveraging fintech innovation to meet the needs of underserved small businesses. With a focus on efficiency, speed, and client satisfaction, FAVO addresses critical gaps in the financial ecosystem while building a platform for long-term growth.

Recent Highlights

  • Fintech Innovation: Initial investments in app development and analytics lay the groundwork for future operational efficiency and improved borrower experience.
  • Operational Scale: A global footprint with over 120 employees combines the agility of a local lender with the reach of an international financial institution.
  • Proven Growth: FAVO’s technology-driven approach has enabled consistent expansion, solidifying its reputation as a trusted partner for small businesses.

Leadership Team

Vincent Napolitano is a Founder and CEO of FAVO Capital Inc. With over two decades of experience in finance and business development, Vincent has been instrumental in building FAVO Capital into a trusted partner for businesses seeking innovative financial strategies. Prior to founding FAVO Capital, Vincent spent 25 years on Wall Street, holding key positions at prominent firms and developing expertise in structuring complex financial deals. He also served as Chief Investment Officer for multiple special purpose vehicles (SPVs), acquiring private stock in pre-IPO unicorn companies such as Facebook and Twitter.

Shaun Quin is a Founding Member and President of FAVO Capital Inc., overseeing the company’s mission to deliver innovative and efficient private credit solutions to small and medium-sized businesses. With over 20 years of global experience as a partner, investor, and director, Shaun brings a strategic and customer-focused approach to his leadership. His expertise in fostering collaboration, building high-performance cultures, and empowering businesses has positioned FAVO Capital as a trusted leader in private lending.

Vaughan Korte, CFO, brings over 15 years of global financial expertise to his role with FAVO Capital Inc. His track record includes managing financial operations for Adidas across 60 countries with budgets exceeding $500 million. Vaughan’s leadership ensures FAVO Capital remains financially resilient, aligning financial strategy with organizational goals and fostering shareholder value.

Glen Steward, Chief Strategy Officer, is a seasoned entrepreneur with over 28 years of experience in the investment and trading industries. He drives FAVO Capital’s strategic initiatives, ensuring the company remains competitive and agile in a rapidly evolving market. Glen has held directorships and board memberships across Mauritius, South Africa, and the United States. His strategic acumen has been pivotal in integrating the FAVO Group of Companies into FAVO Capital Inc., fueling growth and market leadership.

Advisory Board

Bilal Adam, Accounting & Financial Counsel, is a financial expert with over 20 years of experience, including roles as CEO of Stewards Investment Capital. His insights into bespoke investment solutions, including fixed income, equity, and digital assets, support FAVO Capital’s innovative approach to private credit.

Honorable Earnest Hart, Corporate Governance Counsel, brings decades of legal and governance experience, having served as a New York Supreme Court Judge and COO at Columbia University Medical Center. His guidance ensures FAVO Capital maintains robust corporate governance standards.

Rocco Trotta, Business Leadership and Scalability Counsel, is the co-founder of LiRo-Hill and has decades of experience scaling businesses. His expertise in organizational efficiency and talent development strengthens FAVO Capital’s ability to attract excellence across all aspects of the business.

As FAVO Capital redevelops its operations and prepares for an uplisting to Nasdaq, the company is laying the foundation to redefine private credit with emerging fintech solutions and exceptional leadership. Learn more by visiting investors.favocap.com.

Investment Considerations
  • Early-Stage Technology Development: Laying the groundwork for proprietary platforms and scalable digital tools.
  • Significant Market Opportunity: The private credit market is projected to exceed $1.5 trillion by 2025, providing exponential growth potential.
  • Scalable Business Model: Automated processes and data-driven decision-making enable rapid scaling with minimal overhead.
  • Customer-Centric Approach: FAVO’s focus on small businesses and flexible financing solutions addresses critical gaps in the financial ecosystem.
  • Experienced Leadership: A forward-thinking executive team ensures strategic growth and innovation.

FAVO Capital Inc. (OTC: FAVO), closed Tuesday's trading session at $1, up 5.8201%, on 900 volume. The average volume for the last 3 months is 230 and the stock's 52-week low/high is $0.162/$1.08.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.107, up 1.9048%, on 4,287,243 volume. The average volume for the last 3 months is 44,595,743 and the stock's 52-week low/high is $0.0951/$47100.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.